These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Omalizumab for treatment of allergic rhinitis. Vashisht P; Casale T Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175 [TBL] [Abstract][Full Text] [Related]
4. Omalizumab : other indications and unanswered questions. Mankad VS; Burks AW Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081 [TBL] [Abstract][Full Text] [Related]
5. Omalizumab beyond asthma. Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640 [TBL] [Abstract][Full Text] [Related]
6. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications]. Kupryś-Lipińska I; Kuna P Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909 [TBL] [Abstract][Full Text] [Related]
7. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology. Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583 [TBL] [Abstract][Full Text] [Related]
8. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Chang TW; Wu PC; Hsu CL; Hung AF Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539 [TBL] [Abstract][Full Text] [Related]
9. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Holgate ST; Djukanović R; Casale T; Bousquet J Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747 [TBL] [Abstract][Full Text] [Related]
11. Current status of therapy with omalizumab in children. Baena-Cagnani CE; Gómez RM Curr Opin Allergy Clin Immunol; 2014 Apr; 14(2):149-54. PubMed ID: 24535142 [TBL] [Abstract][Full Text] [Related]
12. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Kim DH; Park KY; Kim BJ; Kim MN; Mun SK Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013 [TBL] [Abstract][Full Text] [Related]
13. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis. Félix Toledo R; Negro Alvarez JM; Miralles López JC Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab in allergic diseases, a recent review. Vichyanond P Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590 [TBL] [Abstract][Full Text] [Related]
17. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966 [TBL] [Abstract][Full Text] [Related]
18. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589 [TBL] [Abstract][Full Text] [Related]
19. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps? Verbruggen K; Van Cauwenberge P; Bachert C Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888 [TBL] [Abstract][Full Text] [Related]
20. [Dermatological implications of omalizumab, an anti-IgE antibody]. Di Lucca-Chrisment J Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]